MHLW (Japan)

MHLW (Ministry of Health, Labour and Welfare / 厚生労働省, Kōsei-rōdō-shō) is Japan's national government ministry responsible for health policy, social welfare, labour policy + pensions. MHLW was established 6 January 2001 by the merger of the former Ministry of Health and Welfare (1938-2001) + the Ministry of Labour (1947-2001) as part of Japan's 2001 Central Government Reform. MHLW's headquarters is in Kasumigaseki, Tokyo + the ministry employs approximately 33,000 staff across headquarters, regional bureaus + affiliated agencies. The Minister of Health, Labour and Welfare (大臣, Daijin) is a Cabinet-level political appointee.

Within MHLW the pharmaceutical regulatory ecosystem includes:

• Pharmaceutical Safety Bureau (PSB / 医薬局) — restructured + renamed from the Pharmaceutical Safety and Environmental Health Bureau (PSEHB) in 2024; owns the legal + regulatory framework for medicines, medical devices, regenerative-medicine products, cosmetics + quasi-drugs.
• Health Policy Bureau (医政局) — owns broader health-policy framework including medical-practitioner regulation + hospital regulation.
• Office for Pharmaceutical Industry — within PSB; industrial-policy + industry-engagement function.
• Pharmaceutical Affairs and Food Sanitation Council — MHLW advisory body composed of external experts that advises the Minister on regulatory decisions including marketing authorisations + post-market actions.
• Subcommittee on New Drugs, Subcommittee on Medical Devices, Subcommittee on Regenerative Medicine — PMDA-supported subcommittees of the Pharmaceutical Affairs and Food Sanitation Council that recommend approval decisions to MHLW.
• PMDA (Pharmaceuticals and Medical Devices Agency) — MHLW-affiliated Incorporated Administrative Agency conducting scientific review + GMP / GCP / GVP inspection + safety operations on MHLW's behalf.
• National Institute of Health Sciences (NIHS) — MHLW-affiliated national reference laboratory.
• National Institute of Infectious Diseases (NIID) — MHLW-affiliated national reference laboratory for infectious diseases + vaccines.
• Prefectural + Municipal Health Departments — sub-national health authorities executing MHLW policy at prefectural + municipal level including pharmacy + drug-wholesale licensing.

Legal foundations are the Pharmaceuticals and Medical Devices Act (PMD Act / 薬機法 / Yakukihō, formally the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, Law No. 145 of 1960 as substantially amended in 2014 + subsequent revisions), the Act on the Safety of Regenerative Medicine (2014), the Health Insurance Act, the Pharmacists Act + a substantial body of MHLW Ministerial Ordinances + Notifications (告示 + 通知 / Kokuji + Tsūchi) implementing the PMD Act.

MHLW is the founding ICH Regulatory Member (alongside FDA + EMA, 1990), a PIC/S Participating Authority since July 2014 (through PMDA as the operational inspectorate), an IMDRF Management Committee Member, an active ICMRA participant + the lead Japanese government interlocutor for international pharmaceutical + medical-device regulatory diplomacy. MHLW also chairs the Korea-Japan-China Tripartite regulatory cooperation alongside MFDS + NMPA.

Understanding the MHLW-PMDA relationship is essential to working in Japan. The two are legally distinct but operationally inseparable: MHLW sets policy + issues the formal approval; PMDA conducts the scientific review + inspection that supports MHLW's decision. The split mirrors (but is more formal than) the FDA-HHS or EMA-EU Commission relationships.

• MHLW — legal owner of the PMD Act + the formal authority for 承認 (shōnin — approval) decisions; issues MHLW Ordinances (省令 / Shōrei) + Notifications (告示 / 通知); negotiates international agreements; chairs ICH-MHLW + PIC/S-MHLW representation.
• PMDA — Incorporated Administrative Agency under MHLW conducting scientific review of NDAs + Medical Device applications + Regenerative Medicine applications + Re-examination + Re-evaluation + Quasi-Drug + Cosmetic notifications + GMP / GCP / GLP / GVP inspections.
• MHLW issues the formal 承認 decision based on PMDA's review report + the recommendation of the relevant Pharmaceutical Affairs and Food Sanitation Council Subcommittee.
• PMDA conducts overseas GMP inspections under PIC/S MoU with PMDA as the operational inspectorate; inspection findings feed into MHLW's enforcement framework.
• MHLW handles ICH ratification + Step 4 / Step 5 implementation in Japan; PMDA does the technical drafting + Working Group participation.
• MHLW handles international government-to-government MoUs + regulatory diplomacy (with FDA, EMA, MHRA, Health Canada, TGA, MFDS, NMPA, others); PMDA handles working-level regulator-to-regulator engagement.
• Both are listed in international fora — MHLW as the political/policy member + PMDA as the operational regulator; this is occasionally a source of external confusion.
• Pre-2004 — review was conducted by various MHLW-internal bodies + the predecessor OPSR; the modern PMDA was established 1 April 2004 as the unified scientific-review + inspection agency.
• Post-2014 PMD Act amendment — substantial regulatory modernisation including the regenerative-medicine framework (Class 1 + Class 2 + Class 3), the Conditional + Time-limited Approval pathway + the SAKIGAKE Designation System for pioneer drugs + devices.
• Post-2024 PSB restructure — Pharmaceutical Safety and Environmental Health Bureau renamed + restructured as Pharmaceutical Safety Bureau (PSB), reflecting MHLW's organisational evolution.

The PMD Act (薬機法 / Yakukihō, formally the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, Law No. 145 of 1960) is Japan's foundational pharmaceutical + medical-device + regenerative-medicine + cosmetic + quasi-drug regulatory law. It has been substantially amended over six decades, most importantly:

• 1979 — Major amendment introducing the modern Marketing Authorization Holder (MAH) framework + Re-examination + Re-evaluation systems.
• 2002 — Amendment introducing the modern medical-device regulatory framework with risk-based classification + QMS requirements.
• 2005 — Reorganisation creating the modern PMDA + the unified review framework + Re-examination + Re-evaluation reforms.
• 2014 — Major amendment renaming the law from Pharmaceutical Affairs Law (薬事法 / Yakujihō) to the current Pharmaceuticals and Medical Devices Act (薬機法 / Yakukihō); created the regenerative-medicine framework (Class 1 Conditional + Time-limited + Class 2 + Class 3); created the SAKIGAKE Designation System; modernised medical-device + IVD classification + post-market surveillance.
• 2019 — Amendment strengthening pharmacovigilance + medical-device post-market surveillance + introducing pharmacist-supervised tele-pharmacy.
• 2022 — Amendment strengthening drug-shortage response + supply-chain transparency requirements + post-pandemic regulatory resilience.

Key structural elements include:

• Marketing Authorization Holder (MAH / 製造販売業者) — Japanese-resident entity that holds the 承認 + bears post-market liability + pharmacovigilance responsibility; foreign manufacturers must engage a Japanese MAH or establish a Japanese subsidiary.
• Foreign Special Approval Holder (外国特例承認取得者) — alternative framework allowing certain foreign entities to hold approval directly subject to Japanese in-country agent + MAH-equivalent obligations.
• Approval (承認 / Shōnin) — the formal MHLW marketing-authorisation decision for medicines + medical devices + regenerative-medicine products requiring substantive review.
• Notification (届出 / Todokede) — simpler regulatory submission for quasi-drugs + cosmetics + Class I medical devices not requiring full Approval.
• Three Officers — MHLW Ordinance requires every Japanese MAH to designate three responsible officers: General Marketing Compliance Officer (総括製造販売責任者), Quality Assurance Officer (品質保証責任者) + Safety Management Officer (安全管理責任者).
• MHLW Ordinance 179 (2004) — Japanese GMP for drugs + quasi-drugs; substantively aligned with PIC/S GMP Guide + ICH Q7 / Q9 / Q10.
• MHLW Ordinance 169 (2004) — Japanese QMS for medical devices; substantively aligned with ISO 13485:2016.
• MHLW Notifications + Tsūchi — implementing guidance that operationalises the PMD Act + Ordinances; the principal source of regulatory detail for applicants + sponsors.

MHLW operates two distinctive accelerated-approval pathways that have substantially shaped Japan's standing as a competitive global regulatory venue, particularly for innovative + first-in-class products.

• SAKIGAKE Designation System (先駆け審査指定制度) — introduced by MHLW Notification in 2015 + formalised in the 2020 PMD Act amendment; provides accelerated PMDA review (6-month target vs 12-month standard) + enhanced PMDA + MHLW engagement for products meeting four criteria: (1) world-first innovation, (2) Japan-first development commitment, (3) substantial improvement over existing therapies + (4) serious-disease focus.
• SAKIGAKE has been awarded to a select group of drugs + medical devices + regenerative-medicine products since 2015; designation requires substantial pre-submission engagement with PMDA + MHLW + a commitment to file in Japan first or simultaneously with other major regulators.
• Conditional + Time-limited Approval (条件付き早期承認) — substantively similar to FDA Accelerated Approval + EMA Conditional Marketing Authorisation; approval based on Phase II evidence with mandatory post-marketing confirmatory study + time-limited approval converting to standard approval upon confirmation.
• Conditional + Time-limited Approval was substantially expanded in the 2014 PMD Act amendment + has been applied to several oncology + rare-disease products.
• Regenerative Medicine Class 1 Conditional + Time-limited — the 2014 PMD Act regenerative-medicine framework allows up to 7 years of conditional approval for regenerative-medicine products based on Phase II evidence; this was the world's most progressive ATMP framework until Korea's 2019 Advanced Regenerative Bio Act caught up.
• Orphan Drug Designation (希少疾病用医薬品) — MHLW orphan-drug framework with reduced fees + enhanced PMDA engagement + extended re-examination period (10 years vs 4-8 years standard); applies to drugs for serious diseases affecting fewer than 50,000 patients in Japan.
• Priority Review (優先審査) — PMDA priority review (9-month target vs 12-month standard) for orphan drugs + drugs for serious unmet need; complementary to but distinct from SAKIGAKE.
• Pediatric extension + Pediatric Investigation Plan equivalent — MHLW operates a Pediatric Use development framework with extended re-examination + tax incentives.
• All accelerated pathways operate within the same Marketing Authorization Holder + Three Officers framework — accelerated approval does not relax MAH + post-market obligations.

• ICH Founding Regulatory Member — MHLW is one of the three founding ICH Regulatory Members (alongside FDA + EMA, 1990); chairs + co-chairs ICH Working Groups + has co-developed essentially every ICH Guideline; ICH ratification + Step 4 / Step 5 implementation in Japan flows through MHLW.
• PIC/S Participating Authority since July 2014 (through PMDA as operational inspectorate) — full GMP-inspection reliance with all PIC/S members.
• IMDRF Management Committee Member — co-founder of GHTF + IMDRF; chair / co-chair rotation; lead on IMDRF Working Groups on UDI, QMS, SaMD + AI / ML.
• ICMRA Founding Member — active on pandemic preparedness, supply chain, regulatory innovation + reliance.
• Korea-Japan-China Tripartite — MHLW chairs trilateral regulatory cooperation alongside MFDS + NMPA covering generics, biosimilars, regenerative-medicine + medical devices.
• APEC Regulatory Harmonization Steering Committee (RHSC) — active member contributing on APEC pharmaceutical + medical-device harmonisation.
• Asia-Pacific reach — MHLW + PMDA have substantial influence across Asia-Pacific through bilateral MoUs (with MFDS, NMPA, TGA, HSA, MFDS, FDA Philippines, TFDA Taiwan + others) + Japanese product approvals are often accepted as reliance evidence by smaller Asian regulators.
• Bilateral MoUs — MHLW + PMDA hold MoUs with FDA, EMA, MHRA, Health Canada, TGA, MFDS, NMPA, SFDA, ANVISA + many others; tight cooperation on inspections + safety + information exchange.
• WHO collaboration — MHLW supports WHO programmes through PMDA technical contributions + Japanese government funding; not a WHO PQ submitter for Japanese MAs but provides extensive technical assistance to LMIC NRAs.
• MDSAP Participating Regulator — MHLW + PMDA are MDSAP Participating Regulators with full audit-report reliance.

• MAH not properly established or Three Officers not properly designated — application rejected at PMDA intake or post-approval compliance failure.
• Foreign Special Approval Holder framework misjudged — applicants attempting to use FSAH where MAH route is required.
• SAKIGAKE eligibility misjudged — applicants applying for SAKIGAKE without satisfying the Japan-first commitment or world-first innovation criteria.
• Japanese clinical data requirement misjudged — most new drugs require some Japanese clinical data (Japan-inclusive global trial or Japanese bridging study); foreign-only data rarely sufficient.
• Re-examination period commitments missed — MAH failing to complete prescribed post-marketing studies within re-examination period; MHLW re-examination decision delayed or unfavourable.
• Japanese-language labelling + IFU non-compliant — Japanese labelling has specific MHLW-required content including 効能・効果 (indications), 用法・用量 (dosage), 警告 (warning) + 副作用 (adverse reactions).
• PMDA Consultation strategy not used — applicants failing to engage in pre-submission PMDA Consultations (paid scientific advice) before submission; significantly higher rejection rate.
• MHLW Ordinance 179 GMP gaps — applicants assuming PIC/S GMP compliance is sufficient without addressing Japanese-specific MHLW Ordinance 179 + Notification requirements.
• Data integrity findings — backdating, audit-trail disabled, shared logins, uncontrolled spreadsheets used as raw data; PMDA + PIC/S-level expectations apply.
• Sterile / aseptic process gaps — PMDA inspectorate alignment with EU GMP Annex 1 (2022 revision) creates new expectations + frequent findings.
• MDSAP audit-report packaging gap — MHLW accepts MDSAP but requires PMDA-specific overlay + non-conformity closures.
• Regenerative Medicine framework misjudged — Class 1 / 2 / 3 classification + the Conditional + Time-limited approval framework requires substantial MHLW + PMDA engagement.
• Three Officers responsibility gaps — General Marketing Compliance Officer / Quality Assurance Officer / Safety Management Officer roles not clearly delineated.
• Japan-EU MRA misunderstood — Japan-EU MRA covers medicines GMP-inspection reliance but not marketing-authorisation reliance; applicants need to file separately in Japan even if EU-approved.
• PMDA Re-examination + Re-evaluation strategy not planned — MAHs treating re-examination as routine renewal rather than substantive post-marketing benefit-risk reassessment.

V5 Ultimate provides the operational infrastructure Japanese + foreign-supplier sites need for PMD Act + MHLW Ordinance 179 + Ordinance 169 + MHLW Notifications + PMDA-Tsūchi compliance + MHLW / PMDA readiness.

• MHLW Ordinance 179 GMP control framework — PIC/S-aligned controls (clean rooms, aseptic process, environmental monitoring, EU GMP Annex 1 2022 alignment, computerised systems) with ALCOA+ data-integrity + PMDA inspectorate alignment + MHLW Ordinance 179 + Notification-specific elements.
• Marketing Authorization Holder (MAH) + Three Officers workflow — General Marketing Compliance Officer / Quality Assurance Officer / Safety Management Officer designation + role-management; Japanese MAH establishment-licence scope management; foreign-manufacturer QMS-evidence packaging.
• PMDA submission packaging — eCTD-aligned dossier structure with Japanese Module 1 specifics + PMDA Consultation Document packaging + Japanese clinical data integration.
• SAKIGAKE workflow — Japan-first commitment tracking, world-first innovation evidence packaging, PMDA + MHLW pre-submission consultation management.
• Conditional + Time-limited Approval workflow — Phase II evidence packaging, post-marketing confirmatory study planning + tracking, conversion-to-standard-approval evidence package.
• Regenerative Medicine Class 1 / 2 / 3 workflow — Conditional + Time-limited Approval framework (up to 7 years), cell + gene therapy QMS + GCT-Manufacturing Practice, regenerative-medicine clinical-evaluation packaging.
• Medical Device + IVD registration workflow — Class I-IV classification, MDSAP + ISO 13485 + MHLW Ordinance 169 audit-report packaging, RCB (Registered Certification Body) pathway management for Class II products.
• Re-examination + Re-evaluation workflow — post-marketing study planning + tracking, re-examination application packaging within MHLW-prescribed window, MAH benefit-risk reassessment.
• Japanese labelling + IFU — Japanese-language artwork workflow with two-person review + e-signature; MHLW-required elements (効能・効果 / 用法・用量 / 警告 / 副作用) + Three Officers + MAH details.
• PMDA pharmacovigilance — E2B(R3) ICSR generation, 15-day SUSAR timeline, PSUR / RMP packaging, Safety Management Officer workflow + Japanese Pharmacovigilance Master File.
• Medical device vigilance — FSCA + FSN reporting per MHLW + PMDA framework + IMDRF alignment.
• Korea-Japan-China + APAC bridging — for companies operating across Northeast Asia, V5 surfaces MHLW + MFDS + NMPA harmonised dossier-element reuse alongside national-specific extensions.